Alternative mechanisms for long-acting β2-adrenergic agonists in COPD

Malcolm Johnson, Stephen Rennard

Research output: Contribution to journalReview articlepeer-review

159 Scopus citations


β2-Adrenergic agonists are commonly used as bronchodilators to treat patients with COPD. In addition to prolonged bronchodilation, long-acting β2-agonists (LABAs) exert other effects that may be of clinical relevance. These include inhibition of airway smooth-muscle cell proliferation and inflammatory mediator release, as well as nonsmooth-muscle effects, such as stimulation of mucociliary transport, cytoprotection of the respiratory mucosa, and attenuation of neutrophil recruitment and activation. This review details the possible alternative mechanisms of action of the LABAs, salmeterol and formoterol, in COPD.

Original languageEnglish (US)
Pages (from-to)258-270
Number of pages13
Issue number1
StatePublished - Jul 2001


  • COPD
  • Formoterol
  • Long-acting β-adrenergic agonists
  • Salmeterol

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Alternative mechanisms for long-acting β2-adrenergic agonists in COPD'. Together they form a unique fingerprint.

Cite this